Double-Stranded DNA (dsDNA) Antibodies, IgG, Serum

Clinical Use

Use

The test is useful for evaluating patients with clinical features or at-risk for systemic lupus erythematosus (SLE) and for monitoring disease activity in patients with SLE previously positive for double-stranded DNA IgG antibodies. It detects antibodies to double-stranded DNA (dsDNA), a specific marker for SLE, and aids in the assessment of disease activity. Positive results suggest SLE in the appropriate clinical context, though their performance is subject to the methodological and clinical factors.

Special Instructions

Not provided.

Limitations

Measurements of IgG antibodies to dsDNA are semiquantitative. Variability in test reactivity can occur, and slight changes should not be solely used to anticipate clinical disease course changes. False-positives are typically low titer, and the test alone should not guide treatment decisions. Negative results do not preclude SLE diagnosis, as not all SLE patients have these antibodies detectable at all times.

Test Details

FDA Approved